A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...

This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization ...

A new digital medical device collects real-world data to support personalized care for people with hemophilia A and B, a ...

Living with hemophilia B can be scary. But treatment is so effective that people who have hemophilia generally live just as long as people who don’t have the ...

The high health care burden faced by individuals with hemophilia underscores the urgent need for innovative treatments and improved diversity in clinical trials. Historically, Black, African American ...